In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy
Signed informed consent prior to participation in the study.
Age ≥ 18 years.
Histologically or cytologically confirmed unresectable stage III non-small cell lung cancer.
Completion of concurrent platinum-based chemoradiotherapy
Eligibility for adjuvant durvalumab per standard of care.
At least one tumor lesion or involved lymph node accessible by bronchoscopy or endoscopic/endobronchial ultrasound, suitable for biopsy/fine-needle aspiration (FNA) and fluorescence measurement.
Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
Patient is considered fit to undergo a research bronchoscopy (with or without addition of endobronchial ultrasound; including propofol sedation or general anesthesia if either is indicated).
You may not be if
Known history of infusion reactions to durvalumab, other anti-PD-L1 antibodies, or other monoclonal antibodies, according to the patient's medical history.
Contraindication for bronchoscopy or endoscopic/endobronchial ultrasound (if applicable), including severe uncorrectable coagulopathy, pre-existing severe respiratory insufficiency, or any other clinical reason as judged by the investigator.
Medical or psychiatric conditions compromising the patient's ability to provide informed consent, according to the treating physician.
Pregnancy or breastfeeding. A negative pregnancy test must be available for women of childbearing potential on the day of tracer administration.
Use of an investigational medicinal product within 30 days prior to tracer administration.
Clareo Health | In Vivo Fluorescence Molecular Bronchoscopy of Durvalumab-680LT in Patients With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) After Chemoradiotherapy
